ASND 130.31 Ascendis Pharma A/S
| Range: | 85.285-161.0 | Vol Avg: | 615796 | Last Div: | 0 | Changes: | -1.46 |
| Beta: | 0.64 | Cap: | 7.39B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jan 28 2015 | Empoloyees: | 879 | ||
| CUSIP: | 04351P101 | CIK: | 0001612042 | ISIN: | US04351P1012 | Country: | DK |
| CEO: | Mr. Jan Moller Mikkelsen | Website: | https://ascendispharma.com | ||||
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Stock Details
ASND 191
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
Tazeen Ahmad·Mon Sep 23 2024
Bank of America Securities
ASND 205
Ascendis Pharma price target raised to $205 from $191 at Evercore ISI
Gavin Clark-Gartner·Tue Sep 17 2024
Evercore ISI
ASND 190
Ascendis Pharma (ASND) PT Raised to $190 at Oppenheimer
Leland Gershell·Tue Sep 17 2024
Oppenheimer
ASND 207
Ascendis Pharma price target raised to $207 from $178 at Citi
David Lebowitz·Tue Sep 17 2024
Citigroup
ASND 289
Ascendis Pharma price target raised to $289 from $264 at Wells Fargo
Derek Archila·Tue Sep 17 2024
Wells Fargo
ASND 175
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175
Tazeen Ahmad·Mon Sep 16 2024
Bank of America Securities
ASND 200
Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs
Paul Choi·Mon Sep 16 2024
Goldman Sachs
ASND 178
Citi Reiterates Buy Rating on Ascendis Pharma (ASND)
David Lebowitz·Fri Sep 13 2024
Citigroup
ASND 180
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
Leland Gershell·Thu Sep 05 2024
Oppenheimer
ASND 196
Ascendis Pharma price target raised to $196 from $174 at Jefferies
Kelly Shi·Tue Aug 13 2024
Jefferies
ASND 200
Stifel Starts Ascendis Pharma (ASND) at Buy
Alex Thompson·Thu May 30 2024
Stifel Nicolaus
ASND 140
Ascendis Pharma (ASND) PT Raised to $140 at Morgan Stanley
Vikram Purohit·Wed May 15 2024
Morgan Stanley
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow